nach oben

Erschienen in:

01.07.2021 | Review

Mechanistic and physiological approaches of fecal microbiota transplantation in the management of NAFLD

verfasst von: Manisha Gupta, Pawan Krishan, Amarjot Kaur, Sandeep Arora, Nirupma Trehanpati, Thakur Gurjeet Singh, Onkar Bedi

Erschienen in: Inflammation Research | Ausgabe 7/2021

Einloggen, um Zugang zu erhalten

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a multifaceted disease allied with various metabolic disorders, obesity and dysbiosis. Gut microbiota plays an influential role in the pathogenesis of NAFLD and other metabolic disorders. However, recent scientific upsurge emphasizes on the utility of beneficial gut microbiota and bacteriotherapy in the management of NAFLD. Fecal microbiota transplantation (FMT) is the contemporary therapeutic approach with state-of-the-art methods for the treatment of NAFLD. Other potential therapies include probiotics and prebiotics supplements which are based on alteration of gut microbes to treat NAFLD. In this review, our major focus is on the pathological association of gut microbiota with progression of NAFLD, historical aspects and recent advances in FMT with possible intervention to combat NAFLD and its associated metabolic dysfunctions.

Aller R, Izaola O, Primo D, de Luis D. Cholesteryl ester transfer protein variant (RS1800777) with liver histology in non-alcoholic fatty liver disease patients. Ann Nutr Metab. 2018;73:265–70. https://doi.org/10.1159/000493552.CrossRefPubMed

Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:1061–71. https://doi.org/10.1038/nrgastro.2017.109.CrossRef

Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatolol. 2017;67:862–73. https://doi.org/10.1038/ajg.2013.257.CrossRef

Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature. 2012;489:242. https://doi.org/10.1038/nature11552.CrossRefPubMed

Gérard P. Gut microbiota and obesity. Cell Mol Life Sci. 2016;73:147–62. https://doi.org/10.1007/s00018-015-2061-5.CrossRefPubMed

Chen HT, Huang HL, Li YQ, Xu HM, Zhou YJ. Therapeutic advances in non-alcoholic fatty liver disease: a microbiota-centered view. World J Gastroenterol. 2020;26(16):1901. https://doi.org/10.3748/wjg.v26.i16.1901.CrossRefPubMedPubMedCentral

Marotz CA, Zarrinpar A. Focus: microbiome—treating obesity and metabolic syndrome with fecal microbiota transplantation. Yale J Biol Med. 2016;89:383.PubMedPubMedCentral

Iacono A, Raso GM, Canani RB, Calignano A, Meli R. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J Nutr Biochem. 2011;22(8):699–711. https://doi.org/10.1016/j.jnutbio.2010.10.002.CrossRefPubMed

Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci. 2004;101(44):15718–23. https://doi.org/10.1073/pnas.0407076101.CrossRefPubMedPubMedCentral

10.

Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027. https://doi.org/10.1038/nature05414.CrossRefPubMed

11.

Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci. 2007;104(3):979–84. https://doi.org/10.1073/pnas.0605374104.CrossRefPubMedPubMedCentral

12.

Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, Griffin NW, Lombard V, Henrissat B, Bain JR, Muehlbauer MJ. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013. https://doi.org/10.1126/science.1241214.CrossRefPubMedPubMedCentral

13.

Caesar R, Tremaroli V, Kovatcheva-Datchary P, Cani PD, Bäckhed F. Crosstalk between gut microbiota and dietary lipids aggravates WAT inflammation through TLR signaling. Cell Metab. 2015;22:658–68. https://doi.org/10.1016/j.cmet.2015.07.026.CrossRefPubMedPubMedCentral

14.

Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Ann Rev Pathol. 2010;5:145–71. https://doi.org/10.1146/annurev-pathol-121808-102132.CrossRef

15.

Onkar B, Savera A, Nirupma T, Gayatri R, Pawan K. Molecular and pathological events involved in the pathogenesis of diabetes associated non-alcoholic fatty liver disease. J Clin Exp Hepatol. 2018. https://doi.org/10.1016/j.jceh.2018.10.004.CrossRef

16.

Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2014;59:1174–97. https://doi.org/10.1002/hep.26717.CrossRefPubMed

17.

Yu J, Marsh S, Hu J, Feng W, Wu C. The pathogenesis of nonalcoholic fatty liver disease: interplay between diet, gut microbiota, and genetic background. Gastroenterol Res Pract. 2016. https://doi.org/10.1155/2016/2862173.CrossRefPubMedPubMedCentral

18.

Hochrath K, Schnabl B. Check your microbiota when taking the drug. J Hepatol. 2018;67:18–20. https://doi.org/10.1002/hep.29422.CrossRef

19.

Kolodziejczyk AA, Zheng D, Shibolet O, Elinav E. The role of the microbiome in NAFLD and NASH. EMBO Mol Med. 2019. https://doi.org/10.15252/emmm.201809302.CrossRefPubMed

20.

Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13:412.CrossRef

21.

Luedde T, Schwabe RF. NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2011;8:108–18. https://doi.org/10.1038/nrgastro.2010.213.CrossRefPubMedPubMedCentral

22.

De Groot PF, Frissen MN, de Clercq NC, Nieuwdorp M. Fecal microbiota transplantation in metabolic syndrome: history, present and future. Gut microbes. 2017;28:253–67. https://doi.org/10.1080/19490976.2017.1293224.CrossRef

23.

Lebaka VR, Wee YJ, Narala VR, Joshi VK. Development of new probiotic foods—a case study on probiotic juices. Ther Probiot Unconv Foods. 2018. https://doi.org/10.1016/B978-0-12-814625-5.00004-2.CrossRef

24.

Zhang F, Luo W, Shi Y, Fan Z, Ji G. Should we standardize the 1,700-year-old fecal microbiota transplantation? Am J Gastroenterol. 2012;107:1755. https://doi.org/10.1038/ajg.2012.251.CrossRefPubMed

25.

Zhou Y, Zheng T, Chen H. Microbial intervention as a novel target in treatment of non-alcoholic fatty liver disease progression. Cell Physiol Biochem. 2018;51:2123–35. https://doi.org/10.1159/000495830.CrossRefPubMed

26.

Vrieze A, de Groot PF, Kootte RS, Knaapen M, Van Nood E, Nieuwdorp M. Fecal transplant: a safe and sustainable clinical therapy for restoring intestinal microbial balance in human disease? Best Pract Res Clin Gastroenterol. 2013;27(1):127–37. https://doi.org/10.1016/j.bpg.2013.03.003.CrossRefPubMed

27.

Todesco T, Rao AV, Bosello O, Knaapen M, Van Nood E, Nieuwdorp M. Propionate lowers blood glucose and alters lipid metabolism in healthy subjects. Am J Clin Nutr. 1991;54:860–5. https://doi.org/10.1093/ajcn/54.5.860.CrossRefPubMed

28.

Guo W, Wang P, Liu ZH, Ye P. Analysis of differential expression of tight junction proteins in cultured oral epithelial cells altered by Porphyromonas gingivalis, Porphyromonas gingivalis lipopolysaccharide, and extracellular adenosine triphosphate. Int J Oral Sci. 2018;10:e8. https://doi.org/10.1038/ijos.2017.51.CrossRefPubMedPubMedCentral

29.

Hu S, Wang J, Wang J, Yang H, Yan X, Su L. Fucoidan from Acaudina molpadioides improves insulin resistance by altering gut microbiota dysfunction. J Funct Foods. 2019;57:59–67. https://doi.org/10.1016/j.jff.2019.03.033.CrossRef

30.

Hardie DG, Carling D. The AMP-activated protein kinase: fuel gauge of the mammalian cell? Eur J Biochem. 1997;246(2):259–73. https://doi.org/10.1111/j.1432-1033.1997.00259.x.CrossRefPubMed

31.

Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev. 2009;22(2):240–73. https://doi.org/10.1128/CMR.00046-08.CrossRefPubMedPubMedCentral

32.

Freeland KR, Wolever TM. Acute effects of intravenous and rectal acetate on glucagon-like peptide-1, peptide YY, ghrelin, adiponectin and tumour necrosis factor-α. Br J Nutr. 2010;103(3):460–6. https://doi.org/10.1017/S0007114509991863.CrossRefPubMed

33.

Lee J, Hong SW, Rhee EJ, Lee WY. GLP-1 receptor agonist and non-alcoholic fatty liver disease. Diabetes Metab J. 2012;36(4):262–7.CrossRef

34.

Bull MJ, Plummer NT. Part 1: The human gut microbiome in health and disease. Integr Med. 2014;13:17.

35.

Raman M, Ahmed I, Gillevet PM, Probert CS, Ratcliffe NM, Smith S, Greenwood R, Sikaroodi M, Lam V, Crotty P, Bailey J. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2013;11:868–75. https://doi.org/10.1016/j.cgh.2013.02.015.CrossRefPubMed

36.

Wong VW, Tse CH, Lam TT, Wong GL, Chim AM, Chu WC, Yeung DK, Law PT, Kwan HS, Yu J, Sung JJ. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis–a longitudinal study. PLoS ONE. 2013;8:e62885.CrossRef

37.

Del Chierico F, Nobili V, Vernocchi P, Russo A, De Stefanis C, Gnani D, Furlanello C, Zandonà A, Paci P, Capuani G, Dallapiccola B. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. Hepatology. 2017;65(2):451–64. https://doi.org/10.1002/hep.28572.CrossRefPubMed

38.

Silva HE, Teterina A, Comelli EM, Taibi A, Arendt BM, Fischer SE, Lou W, Allard JP. Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance. Sci Rep. 2018;8:1466. https://doi.org/10.1038/s41598-018-19753-9.CrossRefPubMedPubMedCentral

39.

Wang B, Jiang X, Cao M, Ge J, Bao Q, Tang L, Chen Y, Li L. Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease. Sci Rep. 2016. https://doi.org/10.1038/srep32002.CrossRefPubMedPubMedCentral

40.

Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, Dulai PS, Caussy C, Bettencourt R, Highlander SK, Jones MB. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab. 2017;25:1054–62. https://doi.org/10.1016/j.cmet.2017.04.001.CrossRefPubMedPubMedCentral

41.

Ponziani FR, Bhoori S, Castelli C, Putignani L, Rivoltini L, Del Chierico F, Sanguinetti M, Morelli D, Paroni Sterbini F, Petito V, Reddel S. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in non-alcoholic fatty liver disease. Hepatology. 2018;69:107–20. https://doi.org/10.1002/hep.30036.CrossRefPubMed

42.

Bajaj JS, Fagan A, Sikaroodi M, White MB, Sterling RK, Gilles H, Heuman D, Stravitz RT, Matherly SC, Siddiqui MS, Puri P. Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. Liver Transpl. 2017;23(7):907–14. https://doi.org/10.1002/lt.24754.CrossRefPubMed

43.

Yuan J, Chen C, Cui J, Lu J, Yan C, Wei X, Zhao X, Li N, Li S, Xue G, Cheng W. Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae. Cell Metab. 2019. https://doi.org/10.1016/j.cmet.2019.08.018.CrossRefPubMed

44.

Jha R, Berrocoso JF. Dietary fiber and protein fermentation in the intestine of swine and their interactive effects on gut health and on the environment: a review. Anim Feed Sci Technol. 2016;212:18–26. https://doi.org/10.1016/j.anifeedsci.2015.12.002.CrossRef

45.

Xin J, Zeng D, Wang H, Ni X, Yi D, Pan K, Jing B. Preventing non-alcoholic fatty liver disease through Lactobacillus johnsonii BS15 by attenuating inflammation and mitochondrial injury and improving gut environment in obese mice. Appl Microbiol Biotechnol. 2014;c98:6817–29. https://doi.org/10.1007/s00253-014-5752-1.CrossRef

46.

Jones ML, Martoni CJ, Prakash S. Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial. Eur J Clin Nutr. 2012;22:699–711. https://doi.org/10.1038/ejcn.2012.126.CrossRef

47.

Fuentes MC, Lajo T, Carrión JM, Cuñé J. Cholesterol-lowering efficacy of Lactobacillus plantarum CECT 7527, 7528 and 7529 in hypercholesterolaemic adults. Br J Nutr. 2013;109:1866–72. https://doi.org/10.1017/S000711451200373X.CrossRefPubMed

48.

Hadi A, Mohammadi H, Miraghajani M, Ghaedi E. Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of clinical trials: synbiotic supplementation and NAFLD. Crit Rev Food Sci Nutr. 2008. https://doi.org/10.1080/10408398.2018.1458021.CrossRef

49.

Russo F, Chimienti G, Riezzo G, Pepe G, Petrosillo G, Chiloiro M, Marconi E. Inulin-enriched pasta affects lipid profile and Lp (a) concentrations in Italian young healthy male volunteers. Eur J Nutr. 2008;47:453–9. https://doi.org/10.1007/s00394-008-0748-1.CrossRefPubMed

50.

Van Loo J, Cummings J, Delzenne N, Englyst H, Franck A, Hopkins M, Kok N, Macfarlane G, Newton D, Quigley M, Roberfroid M. Functional food properties of non-digestible oligosaccharides: a consensus report from the ENDO project (DGXII AIRII-CT94-1095). Br J Nutr. 1999;81:121–32. https://doi.org/10.1017/S0007114599000252.CrossRefPubMed

51.

Bajaj JS, Kassam Z, Fagan A, Gavis EA, Liu E, Cox IJ, Kheradman R, Heuman D, Wang J, Gurry T, Williams R. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. J Hepatol. 2017;66(6):1727–38.CrossRef

52.

Sharpton SR, Ajmera V, Loomba R. Emerging role of the gut microbiome in nonalcoholic fatty liver disease: from composition to function. Clin Gastroenterol Hepatol. 2018;17:296–306. https://doi.org/10.1016/j.cgh.2018.08.065.CrossRefPubMedPubMedCentral

53.

Suez J, Zmora N, Zilberman-Schapira G, Mor U, Dori-Bachash M, Bashiardes S, Zur M, Regev-Lehavi D, Brik RB, Federici S, Horn M. Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell. 2018;174:1406–23. https://doi.org/10.1016/j.cell.2018.08.047.CrossRefPubMed

54.

Delaune V, Orci LA, Lacotte S, Peloso A, Schrenzel J, Lazarevic V, Toso C. Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response. Expert Opin Biol Ther. 2018;18:1061–71. https://doi.org/10.1080/14712598.2018.1518424.CrossRefPubMed

55.

Schneider KM, Wirtz TH, Kroy D, Albers S, Neumann UP, Strowig T, Sellge G, Trautwein C. Successful fecal microbiota transplantation in a patient with severe complicated Clostridium difficile infection after liver transplantation. Case Rep Gastroenterol. 2018;12:76–84. https://doi.org/10.1159/000481937.CrossRefPubMedPubMedCentral

56.

Leylabadlo HE, Ghotaslou R, Kafil HS, Feizabadi MM, Moaddab SY, Farajnia S, Sheykhsaran E, Sanaie S, Shanehbandi D, Baghi HB. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies. Eur J Clin Microbiol Infect Dis. 2020;39(4):613–27.CrossRef

57.

Moreira GV, Azevedo FF, Ribeiro LM, Santos A, Guadagnini D, Gama P, Liberti EA, Saad MJ, Carvalho CR. Liraglutide modulates gut microbiota and reduces NAFLD in obese mice. J Nutr Biochem. 2018;62:143–54. https://doi.org/10.1016/j.jnutbio.2018.07.009.CrossRefPubMed

58.

Angelberger S, Reinisch W, Makristathis A, Lichtenberger C, Dejaco C, Papay P, Novacek G, Trauner M, Loy A, Berry D. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol. 2013;108:1620. https://doi.org/10.1038/ajg.2013.257.CrossRefPubMed

59.

Russell GH, Kaplan JL, Youngster I, Baril-Dore M, Schindelar L, Hohmann E, Winter HS. Fecal transplant for recurrent Clostridium difficile infection in children with and without inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2014;58:588–92. https://doi.org/10.1097/MPG.0000000000000283.CrossRefPubMed

60.

Wang S, Xu M, Wang W, Cao X, Piao M, Khan S, Yan F, Cao H, Wang B. Systematic review: adverse events of fecal microbiota transplantation. PLoS ONE. 2016. https://doi.org/10.1371/journal.pone.0161174.CrossRefPubMedPubMedCentral

61.

Baxter M, Colville A. Adverse events in fecal microbiota transplant: a review of the literature. J Hosp Infect. 2016;92:117–22. https://doi.org/10.1016/j.jhin.2015.10.024.CrossRefPubMed

62.

Craven L, Rahman A, Parvathy SN, Beaton M, Silverman J, Qumosani K, Hramiak I, Hegele R, Joy T, Meddings J, Urquhart B. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial. Am J Gastroenterol. 2020;115(7):105510–65. https://doi.org/10.1430/ajg.0000000000000661.CrossRef

63.

Witjes JJ, Smits LP, Pekmez CT, Prodan A, Meijnikman AS, Troelstra MA, Bouter KE, Herrema H, Levin E, Holleboom AG, Winkelmeijer M. Donor fecal microbiota transplantation alters gut microbiota and metabolites in obese individuals with steatohepatitis. Hepatol Commun. 2020;4(11):1578–90. https://doi.org/10.1002/hep4.1601.CrossRefPubMedPubMedCentral

64.

Lechner S, Yee M, Limketkai BN, Pham EA. Fecal microbiota transplantation for chronic liver diseases: current understanding and future direction. Dig Dis Sci. 2020;65(3):897–905.CrossRef

65.

Bajaj JS, Salzman NH, Acharya C, Sterling RK, White MB, Gavis EA, Fagan A, Hayward M, Holtz ML, Matherly S, Lee H. Fecal microbial transplant capsules are safe in hepatic encephalopathy: a phase 1, randomized, placebo-controlled trial. Hepatology. 2019;70(5):1690–703.CrossRef

Titel: Mechanistic and physiological approaches of fecal microbiota transplantation in the management of NAFLD
verfasst von: Manisha Gupta
Pawan Krishan
Amarjot Kaur
Sandeep Arora
Nirupma Trehanpati
Thakur Gurjeet Singh
Onkar Bedi
Publikationsdatum: 01.07.2021
Verlag: Springer International Publishing
Erschienen in: Inflammation Research / Ausgabe 7/2021
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-021-01480-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

SGLT2-Inhibitoren und GLP-1-Rezeptoragonisten im Schlagabtausch

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Wer hat die Nase vorn – SGLT2-Inhibitoren oder GLP-1-Rezeptoragonisten? Diese Frage diskutierten zwei Experten in einer Session auf dem diesjährigen Diabetes-Kongress.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2021

Targeting JAK/STAT signaling pathways in treatment of inflammatory bowel disease

CircRNA circ-ITCH improves renal inflammation and fibrosis in streptozotocin-induced diabetic mice by regulating the miR-33a-5p/SIRT6 axis

Evolution of β-catenin-independent Wnt–GSK3–mTOR signalling in regulation of energy metabolism in isoproterenol-induced cardiotoxicity model

Insight into the longitudinal relationship between chronic subclinical inflammation and obesity from adolescence to early adulthood: a dual trajectory analysis

FSTL1 aggravates OVA-induced inflammatory responses by activating the NLRP3/IL-1β signaling pathway in mice and macrophages